Published within the same month, the SORMAIN trial recruited 83 patients with FLT3-ITD AML and randomized patients to 24 months of sorafenib maintenance therapy or placebo starting between post-transplant day 60 and 100 (10). Here, FLT3 is linked to acute myeloid leukemia.